Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting

November 7, 2022

https://www.globenewswire.com/news-release/2022/11/07/2549596/18421/en/Alaunos-Therapeutics-to-Present-Data-Highlighting-its-hunTR-TCR-Discovery-Platform-at-the-Society-for-Immunotherapy-of-Cancer-2022-Annual-Meeting.html

HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) — Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster presentation highlighting the potential of the Company’s human neoantigen T-cell receptor platform (hunTR) to expand its TCR Library. The data will be presented at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting in Boston, Massachusetts from November 8-12, 2022.

Read more at globenewswire.com

Related news for (TCRT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.